Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
stocks
6 undervalued US shares that crushed earnings
Atlassian and CarMax remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,692.80 | 143.80 | -1.63% |
| CAC 40 | 7,955.01 | 125.73 | -1.56% |
| DAX 40 | 24,886.51 | 577.30 | -2.27% |
| Dow JONES (US) | 49,079.29 | 17.77 | -0.04% |
| FTSE 100 | 10,373.01 | 79.67 | -0.76% |
| HKSE | 22,410.80 | 430.82 | -1.89% |
| NASDAQ | 23,225.76 | 653.44 | -2.74% |
| Nikkei 225 | 56,436.65 | 3,007.56 | -5.06% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 7,070.99 | 104.84 | -1.46% |
| S&P/ASX 200 | 8,592.60 | 137.80 | -1.58% |
| SSE Composite Index | 3,533.79 | 43.82 | -1.22% |